Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles
โ Scribed by Emily J. Pollauf; Kyekyoon Kevin Kim; Daniel W. Pack
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 402 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
โฆ Synopsis
Addition of biodegradable polymer shells surrounding polymeric, drugloaded microparticles offers the opportunity to control drug release rates. A novel fabrication method was used to produce microparticles with precise control of particle diameter and the thickness of the polymer shell. The effect of shell thickness on release of a model drug, piroxicam, has been clearly shown for 2-to 15-mm thick shells of poly(D,Llactide) (PDLL) surrounding a poly(D,L-lactide-co-glycolide) (PLG) core and compared to pure PLG microspheres loaded with piroxicam. Furthermore, the core-shell microparticles are compared to microspheres containing blended polymers in the same mass ratios to demonstrate the importance of the core-shell morphology. Combining PDLL(PLG) microcapsules of different shell thicknesses allows nearly constant release rates to be attained for a period of 6 weeks.
๐ SIMILAR VOLUMES
## Abstract The effect of poly(D,Lโlactideโ__co__โ__para__โdioxanone) (PLADO) as the compatibilizer on the properties of the blend of poly(__para__โdioxanone) (PPDO) and poly(D,Lโlactide) (PDLLA) has been investigated. The 80/20 PPDO/PDLLA blends containing from 1% to 10% of random copolymer PLADO
## Abstract Paclitaxel is one of the best antineoplastic drugs found in nature in the past decades, which has excellent therapeutic effects against a wide spectrum of cancers. Because of its high hydrophobicity, Cremophor EL has to be used as adjuvant in its clinical dosage form (Taxolยฎ), which has